請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66770
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 徐志宏(Chih-Hung Hsu),鄭安理(Ann-Lii Cheng) | |
dc.contributor.author | Li-Chun Lu | en |
dc.contributor.author | 呂理駿 | zh_TW |
dc.date.accessioned | 2021-06-17T00:56:47Z | - |
dc.date.available | 2020-03-12 | |
dc.date.copyright | 2020-03-12 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-02-03 | |
dc.identifier.citation | 1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018
2. Hsiue EH-CH, Lo W-C, Lin H-H, et al: Abstract 286: Forecast of the incidence and etiology of liver cancer in Taiwan, Japan, United States, and United Kingdom: toward harmonization of East and West. Cancer Research 77:286-286, 2017 3. Forner A, Reig M, Bruix J: Hepatocellular carcinoma. Lancet 391:1301-1314, 2018 4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-90, 2008 5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009 6. Bruix J, Qin S, Merle P, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56-66, 2017 7. Kudo M, Finn RS, Qin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163-1173, 2018 8. Abou-Alfa GK, Meyer T, Cheng AL, et al: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379:54-63, 2018 9. Zhu AX, Kang YK, Yen CJ, et al: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:282-296, 2019 10. El-Khoueiry AB, Sangro B, Yau T, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492-2502, 2017 11. Zhu AX, Finn RS, Edeline J, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940-952, 2018 12. Sprinzl MF, Galle PR: Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin Liver Dis 34:376-88, 2014 13. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-93, 2007 14. Gao Q, Wang XY, Qiu SJ, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15:971-9, 2009 15. Calderaro J, Rousseau B, Amaddeo G, et al: Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology 64:2038-2046, 2016 16. Chen ML, Yan BS, Lu WC, et al: Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer 134:319-31, 2014 17. Cao M, Xu Y, Youn JI, et al: Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest 91:598-608, 2011 18. Chang CJ, Yang YH, Chiu CJ, et al: Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. Int J Cancer 142:1878-1889, 2018 19. Chen Y, Liu YC, Sung YC, et al: Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 7:44123, 2017 20. Liu J, Liu Y, Meng L, et al: Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 38:899-907, 2017 21. Jimenez-Sanchez A, Memon D, Pourpe S, et al: Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell 170:927-938 e20, 2017 22. Lindsey KR, Gritz L, Sherry R, et al: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res 12:2526-37, 2006 23. Carrasco J, Van Pel A, Neyns B, et al: Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180:3585-93, 2008 24. Bol KF, Figdor CG, Aarntzen EH, et al: Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 4:e1019197, 2015 25. Zhou SL, Zhou ZJ, Hu ZQ, et al: Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology 150:1646-1658 e17, 2016 26. Kuang DM, Zhao Q, Peng C, et al: Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206:1327-37, 2009 27. Osman TA, Oijordsbakken G, Costea DE, et al: Successful triple immunoenzymatic method employing primary antibodies from same species and same immunoglobulin subclass. Eur J Histochem 57:e22, 2013 28. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-62, 2014 29. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-7, 2014 30. Daud AI, Wolchok JD, Robert C, et al: Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 34:4102-4109, 2016 31. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373:1627-39, 2015 32. Zhang W, Zhu XD, Sun HC, et al: Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16:3420-30, 2010 33. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909-20, 2016 34. Rimm DL, Han G, Taube JM, et al: A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol, 2017 35. Gaule P, Smithy JW, Toki M, et al: A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncol, 2016 36. Shao YY, Wu CH, Lu LC, et al: Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol 60:313-8, 2014 37. Lu LC, Shao YY, Chan SY, et al: Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy. Anticancer Res 34:1047-52, 2014 38. van Kessel CS, Samim M, Koopman M, et al: Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. Eur J Cancer 49:2486-93, 2013 39. Chen ZY, Zhong WZ, Zhang XC, et al: EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 17:978-85, 2012 40. Mete UK, Singh DV, Kakkar N: Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer? Urol Ann 7:387-90, 2015 41. Goasguen N, de Chaisemartin C, Brouquet A, et al: Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. Int J Cancer 127:1028-37, 2010 42. Schmid K, Oehl N, Wrba F, et al: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15:4554-60, 2009 43. Pao W, Ooi CH, Birzele F, et al: Tissue-Specific Immunoregulation: A Call for Better Understanding of the 'Immunostat' in the Context of Cancer. Cancer Discov 8:395-402, 2018 44. Abdi EA, Petrik P: An unusual case of renal cancer showing mixed tumor response to interferon. Am J Med 83:1147-50, 1987 45. Koelzer VH, Rothschild SI, Zihler D, et al: Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 4:13, 2016 46. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47, 2009 47. Nishino M, Ramaiya NH, Hatabu H, et al: Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 14:655-668, 2017 48. Ascierto ML, Makohon-Moore A, Lipson EJ, et al: Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. Clin Cancer Res 23:3168-3180, 2017 49. Oliver AJ, Lau PKH, Unsworth AS, et al: Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Front Immunol 9:70, 2018 50. Remark R, Alifano M, Cremer I, et al: Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 19:4079-91, 2013 51. Baine MK, Turcu G, Zito CR, et al: Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 6:24990-5002, 2015 52. Muller P, Rothschild SI, Arnold W, et al: Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother 65:1-11, 2016 53. Lu LC, Lee YH, Chang CJ, et al: Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer 8:110-120, 2019 54. Khoja L, Kibiro M, Metser U, et al: Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer 115:1186-1192, 2016 55. Tumeh PC, Hellmann MD, Hamid O, et al: Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res 5:417-424, 2017 56. Chan T, Wiltrout RH, Weiss JM: Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol 11:879-89, 2011 57. Tiegs G, Lohse AW: Immune tolerance: what is unique about the liver. J Autoimmun 34:1-6, 2010 58. You Q, Cheng L, Kedl RM, et al: Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 48:978-90, 2008 59. Wu K, Kryczek I, Chen L, et al: Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69:8067-75, 2009 60. Ikeda M, Okusaka T, Ueno H, et al: Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. Jpn J Clin Oncol 38:675-82, 2008 61. Huang AC, Postow MA, Orlowski RJ, et al: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65, 2017 62. Joseph RW, Elassaiss-Schaap J, Kefford RF, et al: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab. Clin Cancer Res, 2018 63. Patel MR, Ellerton J, Infante JR, et al: Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19:51-64, 2018 64. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60, 2010 65. Paley MA, Kroy DC, Odorizzi PM, et al: Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338:1220-5, 2012 66. Lu LC, Chang CJ, Hsu CH: Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma 6:71-84, 2019 67. Khan KA, Kerbel RS: Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15:310-324, 2018 68. Fukumura D, Kloepper J, Amoozgar Z, et al: Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325-340, 2018 69. Kim CG, Jang M, Kim Y, et al: VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol 4: eaay0555, 2019 70. Stein S, Pishvaian MJ, Lee MS, et al: Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Journal of Clinical Oncology 36:4074-4074, 2018 71. Ikeda M, Sung MW, Kudo M, et al: A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). Journal of Clinical Oncology 36:4076-4076, 2018 72. Xu J-M, Zhang Y, Jia R, et al: Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial. Journal of Clinical Oncology 36:4075-4075, 2018 73. Cheng A-L, Qin S, Ikeda M, et al: LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Annals of Oncology 30, 2019 74. Long GV, Dummer R, Hamid O, et al: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20:1083-1097, 2019 75. Lin YY, Tan CT, Chen CW, et al: Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Semin Liver Dis 38:379-388, 2018 76. Shigeta K, Datta M, Hato T, et al: Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology, 2019 [Epub ahead of print] 77. Stubbington MJT, Rozenblatt-Rosen O, Regev A, et al: Single-cell transcriptomics to explore the immune system in health and disease. Science 358:58-63, 2017 78. Vasaturo A, Di Blasio S, Verweij D, et al: Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. Histopathology 70:643-649, 2017 79. Feng Z, Jensen SM, Messenheimer DJ, et al: Multispectral Imaging of | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66770 | - |
dc.description.abstract | 肝細胞癌(肝癌)一直以來都是全球死亡率前幾名的癌症之一。晚期肝癌病患無法接受局部治療,而全身性治療,包括「抗血管新生標靶藥物」和「抗計畫性細胞死亡蛋白-1 (PD-1)為主的免疫檢查點抑制劑(ICIs)」,是標準治療。近來,腫瘤微環境(TME)和全身性治療療效間的關係已成為主要的研究課題。蕾莎瓦 (sorafenib)為一抑制多重激酶的標靶藥物 (包含抗血管新生的療效),也是第一個被核准在晚期肝癌患者使用的藥物,過去研究指出sorafenib具有多重免疫調節的作用,但是其對晚期肝癌TME內的計畫性細胞死亡配位基-1 (PD-L1)表現的影響並不清楚。另外,TME的免疫組成會影響ICIs的療效,但是在肝癌不同器官的免疫組成,是否會造成ICIs在不同器官轉移腫瘤的差別反應也不清楚。
在本研究的第一部份,要驗證的假設為:sorafenib會對肝癌TME內的PD-L1表現有影響。我們回顧有接受過sorafenib的晚期肝癌病患,收集其sorafenib治療前後的配對腫瘤檢體,利用免疫組織染色,半定量分析檢體內腫瘤細胞(TCs)及免疫細胞(ICs)其細胞膜上PD-L1的表現。在23對可分析的檢體中,我們發現ICs的PD-L1表現在sorafenib治療惡化後的檢體顯著高於治療前的;然而,TCs的PD-L1表現在sorafenib治療前後並無顯著差異。我們進一步證明,這些表現PD-L1的ICs,也同步表現巨噬細胞的標記CD68,暗示這些表現PD-L1的巨噬細胞在sorafenib治療後而惡化的肝細胞癌可能有特殊意義。 在本研究的第二部份,要驗證的假設為:各器官TME不同的免疫組成,會造成在各器官內的肝癌腫瘤對ICIs的差別反應。我們回顧曾接受ICIs治療並有可量測腫瘤大小的晚期肝癌病患,分別評估ICIs對其肝、肺、淋巴結、及腹腔內轉移腫瘤的反應率。在75位接受分析的晚期肝癌病患中,有58、34、19及18位患者有可量測之肝、肺、淋巴結、及腹腔內轉移腫瘤,其相對應的特定器官腫瘤反應率分別為22.4%、41.2%、26.3%、及38.9%。在39位同時有肝臟腫瘤及肝外轉移的患者中,12位其肝外轉移腫瘤有獲得控制,但是肝臟腫瘤卻惡化;反之只有四位患者肝臟腫瘤獲得控制,但是肝外轉移腫瘤有惡化(P = .046, McNemar test)。而在16位治療前只有肝臟腫瘤和肺部轉移的患者中,8位其肺部轉移獲得控制,但是肝臟腫瘤卻惡化;反之沒有一位患者有肝臟腫瘤獲得控制,但是肺部轉移腫瘤卻惡化的情形(P = .005)。在本部分的研究,我們發現肝內的肝癌反應率似乎比肝外轉移的腫瘤來得差,而肺部轉移的肝癌對ICIs的反應率最好,暗示TME的免疫組成,會影響對ICIs的療效。 為了進一步探究上述「ICIs對肝癌之不同器官轉移的療效差別反應」之可能機轉,我們利用BNL小鼠肝癌細胞株,分別建立包括原位肝臟肝癌、皮下、及肺臟植入肝癌的同源小鼠模式。我們分析未接受治療的不同器官肝癌小鼠模式,分離腫瘤浸潤CD45陽性白血球和分析其次族群細胞組成,發現肝臟腫瘤比肺部腫瘤有趨勢上較高比例的巨噬細胞及骨髓抑制細胞,不過CD4及CD8陽性T細胞在肝臟及肺部腫瘤的比例則相近。然而,肝臟腫瘤浸潤的CD8 T細胞,比起其他器官腫瘤的有較高比例會表現衰竭標記。此外,我們發現VEGF和其他一些免疫抑制細胞激素,在未接受治療的原位肝腫瘤內比皮下腫瘤來的高;而在PD-L1抗體治療後,其他免疫抑制激素在原位肝腫瘤內有下降,但VEGF和IDO等的表現仍持續比皮下腫瘤顯著的高。在接受PD-L1抗體治療後,我們發現皮下植入的肝癌腫瘤療效好,而原位肝臟植入的肝癌腫瘤反應較差。整體而言,我們的小鼠模式研究結果發現原位肝癌的TME,比植入其他器官的更傾向免疫抑制,支持「不同器官相異的免疫組成,可能影響ICIs的治療效果」。 總結上述研究,首先我們發現在sorafenib治療後惡化的肝癌檢體,其ICs (特別是巨噬細胞) 的PD-L1會顯著上升。其次,我們利用臨床肝癌病人的資料證實,各器官內的肝癌腫瘤對ICIs有差別反應,肝內的肝癌反應率比肝外轉移的腫瘤來得差。在機轉的研究上,我們分析小鼠原位肝癌,有較高比例的巨噬細胞、有較多的衰竭CD8 T細胞、及較高表現的VEGF,使得肝內TME傾向免疫抑制,因此可造成ICIs的療效比其他器官的肝轉移來得差。我們的研究成果可提供未來晚期肝癌全身性治療發展的參考。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma (HCC) has been the leading cause of cancer mortality globally for decades. In cases of advanced HCC, for which locoregional therapy is unsuitable, systemic anticancer therapy through either antiangiogenic agents or anti-programmed-cell-death protein 1 (PD-1)-based immune checkpoint inhibitors (ICIs) is the standard of care. Recently, the interaction between the tumor microenvironment (TME) and systemic therapy response has been a major focus of research. Sorafenib, a multikinase inhibitor with antiangiogenic properties and the first systemic therapy approved for HCC, has been demonstrated to exhibit various immunomodulatory effects. However, the impact of sorafenib on programmed death ligand-1 (PD-L1) expression in the TME of advanced HCC was unclear. In addition, the antitumor effects of ICIs are influenced by the immune contexture of the TME. However, whether distinct immune contextures in different organ systems contribute to the variable tumor response to ICIs in HCC was unknown.
The first part of the thesis addressed the hypothesis that sorafenib treatment affects the expression of PD-L1 in the TME of HCC. We identified patients who received sorafenib for advanced HCC and who had paired tumor tissues obtained before and after sorafenib treatment. We analyzed the tissue slides using immunohistochemistry to semiquantitatively score the membrane PD-L1 staining in tumor cells (TCs) or tumor-infiltrating immune cells (ICs). In 23 paired HCC tissues, PD-L1 expression in ICs was increased in HCC tissues after sorafenib treatment. However, PD-L1 expression in TCs did not increase significantly after sorafenib treatment. We also demonstrated that PD-L1-expressing ICs were highly co-localized with CD68-positive tumor-infiltrating macrophages, suggesting that PD-L1-expressing macrophages play roles in HCC progression after treatment with sorafenib. The second part of the thesis explored the hypothesis that the distinct immune contexture of the TME is associated with variable tumor response to ICIs in HCC. We reviewed data from patients with advanced HCC who had received ICIs and had measurable diseases. The objective response to ICIs in tumors located in different organ systems—such as the liver, lung, lymph nodes, and other intra-abdominal sites—was evaluated independently. Among the 75 enrolled patients, 58, 34, 19, and 18 patients had measurable hepatic tumors and lung, lymph node, and other intra-abdominal metastases, respectively, with the corresponding organ-specific objective response rates being 22.4%, 41.2%, 26.3%, and 38.9%. Among the 39 patients who had both hepatic and extrahepatic tumors, 12 had disease control in the extrahepatic tumors but progressive disease (PD) in the hepatic tumors, whereas only 4 exhibited disease control in the hepatic tumors but PD in the extrahepatic tumors (P = .046). Among the 16 patients with evaluable tumors in only the liver and lung at baseline, 8 had disease control in the lung and PD in the liver, and none had disease control in the liver but PD in the lung (P = .005). In the present study, we demonstrated that hepatic tumors of HCC are less responsive to ICIs than extrahepatic lesions, and lung metastases respond most favorably to ICIs, suggesting that the TME influences the efficacy of ICIs. To explore further the mechanisms underlying the aforementioned organ-specific differential responses to ICI treatment in HCC, we employed a syngeneic mouse liver cancer model in immunocompetent mice. We used BNL mouse liver cancer cells to establish orthotopic, subcutaneous, and lung HCC mouse models independently. We isolated tumor-infiltrating CD45+ leukocytes from untreated tumors at various organ sites. The percentages of overall macrophages and myeloid-derived suppressor cells in liver tumors were numerically higher than those in lung tumors. Conversely, the overall percentages of CD4+ and CD8+ T cells were similar between liver and lung tumors. However, the tumor-infiltrating CD8+ T cells were more exhausted in the liver tumors than in tumors of other organs. In addition, we evaluated the soluble factors in untreated liver and subcutaneous tumors. We observed that the levels of vascular endothelial growth factor (VEGF) and some other immunosuppressive cytokines were higher in the liver than in subcutaneous tumors. After treatment with PD-L1, although the levels of other immunosuppressive cytokines were decreased in the liver, the levels of VEGF and indoleamine 2,3- dioxygenase remained high in liver tumors. Anti-PD-L1 antibody or isotype control was administered to the orthotopic, subcutaneous, or combination models. The results showed that orthotopic HCC tumors responded more poorly to anti-PD-L1 therapy than subcutaneous HCC tumors. Overall, the data demonstrated that BNL mouse liver cancer cells, when implanted in the liver, were associated with a more immunosuppressive TME than those implanted in other organs. The results supported that the distinct immune contextures of different organ sites influenced the efficacy of ICI treatment in mouse HCC models. Overall, we found that increased PD-L1 expression in ICs, mainly macrophages, was associated with HCC progression after treatment with sorafenib. In addition, we demonstrated organ-specific responses to ICIs in patients with advanced HCC. HCC in the liver was less responsive to ICIs than were extrahepatic metastases. We demonstrated mechanistically that orthotopic liver tumors had higher percentages of macrophages, more exhausted CD8+ T cells, and higher VEGF levels, which could render the TME more immunosuppressive and lead to a poorer ICI response than in other organ systems. Our findings provide insights that could facilitate the development of systemic therapy for advanced HCC in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:56:47Z (GMT). No. of bitstreams: 1 ntu-109-D02453002-1.pdf: 2531038 bytes, checksum: b8ea313e1068e24314da9bbd1cc20d2b (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書 i
Preface ii 中文摘要 iii Abstract v Chapter I Background 1 Chapter II The impact of sorafenib on PD-L1 expression in the HCC tumor microenvironment 4 2.1 Introduction 4 2.2 Methods 5 2.3 Results 7 2.4 Discussion 10 Chapter III Organ-specific tumor response to ICIs in HCC 14 3.1 Introduction 14 3.2 Methods 14 3.3 Results 16 3.4 Discussion 18 Chapter IV Exploring the mechanisms underlying the organ-specific responses to ICIs in HCC 23 4.1 Introduction 23 4.2 Methods 23 4.3 Results 25 4.4 Discussion 27 Chapter V Summary and future perspectives 30 Chapter VI Figures 32 Chapter VII Tables 45 Reference 49 | |
dc.language.iso | en | |
dc.title | 肝細胞癌的免疫組成:從標靶藥物到免疫治療 | zh_TW |
dc.title | Immune Contexture of Hepatocellular Carcinoma: From Sorafenib to Immune Checkpoint Inhibitors | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳立宗(Li-Tzong Chen),高嘉宏(Jia-Horng Kao),趙毅(Yee Chao) | |
dc.subject.keyword | 肝細胞癌,蕾莎瓦,計畫性細胞死亡配位基-1,免疫檢查點抑制劑,腫瘤微環境,免疫組成, | zh_TW |
dc.subject.keyword | hepatocellular carcinoma,sorafenib,PD-L1,immune checkpoint inhibitors,tumor microenvironment,immune contexture, | en |
dc.relation.page | 57 | |
dc.identifier.doi | 10.6342/NTU202000150 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-02-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 腫瘤醫學研究所 | zh_TW |
顯示於系所單位: | 腫瘤醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-109-1.pdf 目前未授權公開取用 | 2.47 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。